Deoxycholic Acid Obesity Drugs Global Market Report 2026
상품코드:1951691
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
데옥시콜산 비만 치료제 시장 규모는 최근 빠르게 확대하고 있습니다. 2025년 5억 달러에서 2026년에는 5억 7,000만 달러로, CAGR 14.4%로 성장할 것으로 예상됩니다. 지난 수년간의 성장에는 미용 치료에 대한 소비자의 인식 개선, 의료 미용 클리닉의 확대, 최소침습적 시술의 수용 확대, 승인된 데옥시콜산 제제의 가용성, 가처분 소득의 증가 등이 요인으로 작용한 것으로 보입니다.
데옥시콜산계 비만 치료제 시장 규모는 향후 몇 년간 급속한 성장이 전망됩니다. 2030년에는 14.1%의 CAGR로 9억 7,000만 달러에 달할 전망입니다. 예측 기간 동안 성장 요인으로는 맞춤형 미용 치료에 대한 수요 증가, 복합 미용 프로토콜의 확대, 바디 컨투어링 시술에 대한 관심 증가, 미용 의약품 혁신에 대한 투자 확대, 신흥 시장에서의 보급률 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 비수술적 지방 감소 시술의 채택 증가, 주사형 미용 치료의 수요 확대, 복합 지방 분해 요법의 개발 진전, 클리닉 기반 바디 컨투어링 서비스 확대, 환자 개개인의 미용적 성과에 대한 관심 강화 등이 있습니다.
비만율의 증가는 향후 몇 년 동안 데옥시콜산계 비만 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 비만율은 체질량지수(BMI)를 기준으로 과체중 또는 비만으로 분류되는 인구의 비율을 나타냅니다. 비만율의 증가는 주로 가공식품과 당분이 함유된 음료의 과다 섭취와 같은 건강에 해로운 식습관으로 인해 과도한 칼로리가 체지방으로 축적되는 것이 주요 원인으로 꼽힙니다. 데옥시콜산계 비만 치료제는 잉여 지방세포를 분해 및 제거하여 비만율 감소에 기여하고, 표적 부위의 지방 감소와 바디 컨투어링 개선을 가져옵니다. 예를 들어, 영국 정부 기관인 Office for Health Improvement and Disparities(Office for Health Improvement and Disparities)에 따르면, 2025년 5월 기준 영국 18세 이상 성인의 약 64.5%가 2023년부터 2024년까지 과체중 또는 비만인 것으로 추정하고 있습니다. 비만 상태에 있는 것으로 추정되고 있습니다. 이는 2022-2023년 64.0%에서 증가한 수치입니다. 그 결과, 비만율의 증가는 데옥시콜산계 비만치료제 시장의 성장을 촉진하고 있습니다.
향후 몇 년 동안 비수술적 바디 컨투어링 솔루션에 대한 수요 증가는 데옥시콜산 비만 치료제 시장의 성장을 견인할 것으로 예상됩니다. 비수술적 바디 컨투어링 솔루션은 수술이나 다운타임 없이 지방을 감소시키고, 피부를 조이고, 체형을 교정하는 기술(냉동지방분해, 초음파, 고주파, 레이저 등)을 이용한 비침습적 또는 최소침습적 시술을 말합니다. 기존 수술에 비해 통증이 적고, 위험이 적으며, 회복 기간이 거의 또는 전혀 필요하지 않으면서도 효과적인 지방 감소와 피부 타이트닝을 위한 안전하고 덜 침습적인 대안을 찾는 소비자가 증가함에 따라 비수술적 바디 컨투어링에 대한 수요가 증가하고 있습니다. 데옥시콜산계 비만 치료제는 대상 부위에 주입하여 국소 지방세포를 분해 및 제거하여 침습적 수술 없이도 완고한 지방 침착 감소와 체형 개선을 가져와 비수술적 바디 컨투어링을 돕습니다. 예를 들어, 미국에 본사를 둔 전문 기관인 국제미용성형외과학회(ISAPS)에 따르면, 2024년 6월 기준 2023년 보툴리눔톡신은 전 연령대 및 성별을 불문하고 비수술적 치료의 선두를 유지했으며, 성형외과 의사에 의한 치료 건수는 전 세계적으로 880만 건에 달했습니다. 반면, 히알루론산을 이용한 치료는 29% 증가하여 550만 건에 달했습니다. 따라서 비수술적 바디 컨투어링 솔루션에 대한 수요 증가가 데옥시콜산계 비만 치료제 시장의 성장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
Deoxycholic acid obesity drugs are pharmaceutical formulations containing deoxycholic acid, a naturally occurring bile acid, developed to break down and remove localized fat deposits. They are primarily used in non-surgical fat reduction treatments, focusing on areas such as the chin, abdomen, and other stubborn fat regions.
The primary types of deoxycholic acid obesity drugs include ATX-101 (deoxycholic acid injection, also known as Kybella or Belkyra), experimental or compounded deoxycholic acid formulations, combination therapies, and oral deoxycholic acid products. ATX-101 (Deoxycholic Acid Injection, or Kybella, or Belkyra) refers to the commercially approved injectable forms of deoxycholic acid used for targeted fat reduction. These are available in various formulations, including injectable and topical options, and are distributed through multiple channels, such as direct sales, retail pharmacies, and online pharmacies. These drugs are used for a range of applications, including submental fat reduction, abdominal fat reduction, thighs, arms, and flanks, lipomas, localized fat, and cellulite management, and are primarily utilized by different end-users, including aesthetic clinics, dermatology clinics, plastic surgery centers, hospitals, and administration.
Tariffs are influencing the deoxycholic acid obesity drugs market by increasing costs of imported active pharmaceutical ingredients, formulation excipients, sterile packaging materials, and medical-grade syringes. North America and Europe are most affected due to dependence on imported pharmaceutical inputs, while Asia-Pacific faces higher costs for formulation and distribution components. These tariffs are contributing to higher treatment costs and pricing pressure in aesthetic clinics. However, they are also driving local formulation manufacturing, regional supply chain optimization, and increased investment in domestic aesthetic pharmaceutical production.
The deoxycholic acid obesity drugs market research report is one of a series of new reports from The Business Research Company that provides deoxycholic acid obesity drugs market statistics, including deoxycholic acid obesity drugs industry global market size, regional shares, competitors with a deoxycholic acid obesity drugs market share, detailed deoxycholic acid obesity drugs market segments, market trends and opportunities, and any further data you may need to thrive in the deoxycholic acid obesity drugs industry. This deoxycholic acid obesity drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The deoxycholic acid obesity drugs market size has grown rapidly in recent years. It will grow from $0.5 billion in 2025 to $0.57 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to increasing consumer awareness of aesthetic treatments, expansion of medical aesthetics clinics, rising acceptance of minimally invasive procedures, availability of approved deoxycholic acid formulations, growth in disposable income.
The deoxycholic acid obesity drugs market size is expected to see rapid growth in the next few years. It will grow to $0.97 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to increasing demand for personalized aesthetic treatments, expansion of combination aesthetic protocols, rising focus on body contouring procedures, growing investments in aesthetic drug innovation, increasing penetration in emerging markets. Major trends in the forecast period include increasing adoption of non-surgical fat reduction procedures, rising demand for injectable aesthetic treatments, growing development of combination lipolytic therapies, expansion of clinic-based body contouring services, enhanced focus on patient-specific aesthetic outcomes.
The increasing obesity rates are expected to drive the growth of the deoxycholic acid obesity drug market in the coming years. Obesity rates indicate the proportion of a population categorized as overweight or obese based on body mass index (BMI). The rise in obesity rates is largely due to unhealthy dietary patterns, including high consumption of processed foods and sugary beverages, which lead to excess calorie storage as body fat. Deoxycholic acid obesity drugs aid in lowering obesity rates by breaking down and removing surplus fat cells, resulting in targeted fat reduction and enhanced body contour. For example, in May 2025, according to the Office for Health Improvement and Disparities, a UK government agency, an estimated 64.5% of adults aged 18 and above in England were overweight or living with obesity from 2023 to 2024, up from 64.0% in 2022 to 2023. Consequently, the rising obesity rates are fueling the growth of the deoxycholic acid obesity drug market.
The increasing demand for non-surgical body contouring solutions is expected to drive the growth of the deoxycholic acid obesity drug market in the coming years. Non-surgical body contouring solutions refer to non-invasive or minimally invasive procedures that utilize technologies such as cryolipolysis, ultrasound, radiofrequency, or lasers to reduce fat, tighten skin, and reshape the body without surgery or downtime. The demand for non-surgical body contouring is growing as consumers seek safer, minimally invasive alternatives to traditional cosmetic surgery that offer effective fat reduction and skin tightening with minimal pain, lower risk, and little to no recovery time. Deoxycholic acid obesity drugs assist in non-surgical body contouring by breaking down and eliminating localized fat cells when injected into targeted areas, resulting in a reduction of stubborn fat deposits and improved body shape without the need for invasive surgery. For example, in June 2024, according to the International Society of Aesthetic Plastic Surgery, a US-based professional organization, botulinum toxin remained the leading non-surgical procedure for all genders and age groups in 2023, with plastic surgeons performing 8.8 million treatments globally, while hyaluronic acid procedures increased 29% to reach 5.5 million. Therefore, the growing demand for non-surgical body contouring solutions is driving the expansion of the deoxycholic acid obesity drug market.
Major companies operating in the deoxycholic acid obesity drug market are concentrating on developing advanced products, such as injectable deoxycholic acid obesity drugs, to improve treatment effectiveness and enhance patient outcomes. Injectable deoxycholic acid obesity drugs utilize deoxycholic acid, a compound that breaks down fat cells, and are administered via injection to specifically target and reduce fat in particular areas. For example, in March 2024, LG Chem Ltd., a South Korea-based chemicals company, launched Bellacholine for the reduction of submental fat. This nonsurgical injection is designed to reduce moderate to severe submental fat (double chin) by safely destroying fat cells with deoxycholic acid. It provides benefits such as body-compatible pH, minimal sedimentation, and support for skin elasticity through collagen synthesis.
Major companies operating in the deoxycholic acid obesity drugs market are AbbVie Inc., Cipla Ltd., Glenmark Life Sciences Limited, Curia Global Inc., Daewoong Pharmaceutical Co. Ltd., Actylis, ICE Pharma, Cayman Chemical Company, Nacalai Tesque Inc., Sichuan Huiyu Pharmaceutical, Conscientia Industrial, Manus Aktteva Biopharma LLP, Jeevan Chemicals & Pharmaceuticals, Anhui Chem-Bright Bioengineering Co. Ltd., GlpBio Technology LLC, Legere Pharmaceuticals, Otto Chemie Pvt. Ltd., BOC Sciences, Guangzhou Green Cross Pharmaceutical, Prodotti Chimici e Alimentari S.P.A
North America was the largest region in the deoxycholic acid obesity drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxycholic acid obesity drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the deoxycholic acid obesity drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The deoxycholic acid obesity drugs market consists of sales of injection lipolysis with bile acid derivatives, investigational and preclinical agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Deoxycholic Acid Obesity Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses deoxycholic acid obesity drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for deoxycholic acid obesity drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The deoxycholic acid obesity drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Type: ATX-101 (Deoxycholic Acid Injection Or Kybella Or Belkyra); Experimental Or Compounded Deoxycholic Acid Formulations; Combination Therapies; Oral Deoxycholic Acid Products
2) By Formulation: Injectable; Topical
3) By Distribution Channel: Direct Sales; Retail Pharmacies; Online Pharmacies
4) By Application: Submental Fat Reduction; Abdominal Fat Reduction; Thighs Arms And Flanks; Lipomas And Localized Fat; Cellulite Management
5) By End-User: Aesthetic Clinics; Dermatology Clinics; Plastic Surgery Centers; Hospitals; Home Administration
Subsegments:
1) By ATX-101 (Deoxycholic Acid Injection or Kybella or Belkyra): Standard Injectable; High-Purity Formulations; Combination Injection Therapies
2) By Experimental Or Compounded Deoxycholic Acid Formulation: Clinical Trial Formulations; Compounded Customized Formulations
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.1 Increasing Adoption Of Non-Surgical Fat Reduction Procedures
4.2.2 Rising Demand For Injectable Aesthetic Treatments
4.2.3 Growing Development Of Combination Lipolytic Therapies
4.2.4 Expansion Of Clinic-Based Body Contouring Services
4.2.5 Enhanced Focus On Patient-Specific Aesthetic Outcomes
5. Deoxycholic Acid Obesity Drugs Market Analysis Of End Use Industries
5.1 Aesthetic Clinics
5.2 Dermatology Clinics
5.3 Plastic Surgery Centers
5.4 Hospitals
5.5 Medical Aesthetic Practices
6. Deoxycholic Acid Obesity Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Deoxycholic Acid Obesity Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Deoxycholic Acid Obesity Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Deoxycholic Acid Obesity Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Deoxycholic Acid Obesity Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Deoxycholic Acid Obesity Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Deoxycholic Acid Obesity Drugs Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.1. Global Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
ATX-101 (Deoxycholic Acid Injection Or Kybella Or Belkyra), Experimental Or Compounded Deoxycholic Acid Formulations, Combination Therapies, Oral Deoxycholic Acid Products
9.2. Global Deoxycholic Acid Obesity Drugs Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Injectable, Topical
9.3. Global Deoxycholic Acid Obesity Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Direct Sales, Retail Pharmacies, Online Pharmacies
9.4. Global Deoxycholic Acid Obesity Drugs Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Submental Fat Reduction, Abdominal Fat Reduction, Thighs Arms And Flanks, Lipomas And Localized Fat, Cellulite Management
9.5. Global Deoxycholic Acid Obesity Drugs Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Aesthetic Clinics, Dermatology Clinics, Plastic Surgery Centers, Hospitals, Home Administration
9.6. Global Deoxycholic Acid Obesity Drugs Market, Sub-Segmentation Of ATX-101 (Deoxycholic Acid Injection Or Kybella Or Belkyra), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Standard Injectable, High-Purity Formulations, Combination Injection Therapies
9.7. Global Deoxycholic Acid Obesity Drugs Market, Sub-Segmentation Of Experimental Or Compounded Deoxycholic Acid Formulation, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Deoxycholic Acid Obesity Drugs Market
12.1. China Deoxycholic Acid Obesity Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Deoxycholic Acid Obesity Drugs Market
13.1. India Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Deoxycholic Acid Obesity Drugs Market
14.1. Japan Deoxycholic Acid Obesity Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Deoxycholic Acid Obesity Drugs Market
15.1. Australia Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Deoxycholic Acid Obesity Drugs Market
16.1. Indonesia Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Deoxycholic Acid Obesity Drugs Market
17.1. South Korea Deoxycholic Acid Obesity Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Deoxycholic Acid Obesity Drugs Market
19.1. South East Asia Deoxycholic Acid Obesity Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Deoxycholic Acid Obesity Drugs Market
20.1. Western Europe Deoxycholic Acid Obesity Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Deoxycholic Acid Obesity Drugs Market
21.1. UK Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Deoxycholic Acid Obesity Drugs Market
22.1. Germany Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Deoxycholic Acid Obesity Drugs Market
23.1. France Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Deoxycholic Acid Obesity Drugs Market
24.1. Italy Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Deoxycholic Acid Obesity Drugs Market
25.1. Spain Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Deoxycholic Acid Obesity Drugs Market
26.1. Eastern Europe Deoxycholic Acid Obesity Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Deoxycholic Acid Obesity Drugs Market
27.1. Russia Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Deoxycholic Acid Obesity Drugs Market
28.1. North America Deoxycholic Acid Obesity Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Deoxycholic Acid Obesity Drugs Market
29.1. USA Deoxycholic Acid Obesity Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Deoxycholic Acid Obesity Drugs Market
31.1. South America Deoxycholic Acid Obesity Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Deoxycholic Acid Obesity Drugs Market
32.1. Brazil Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Deoxycholic Acid Obesity Drugs Market
33.1. Middle East Deoxycholic Acid Obesity Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Deoxycholic Acid Obesity Drugs Market
34.1. Africa Deoxycholic Acid Obesity Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Deoxycholic Acid Obesity Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Deoxycholic Acid Obesity Drugs Market Regulatory and Investment Landscape
36. Deoxycholic Acid Obesity Drugs Market Competitive Landscape And Company Profiles
